Impact of CGHS Rate Changes on M&A and Investment Opportunities in Indian Hospitals

In a significant move on October 13, 2025, the Central Government Health Scheme (CGHS) announced comprehensive changes to reimbursement rates for about 2,000 medical procedures, with an average increase of 25-30%. This momentous regulatory shift has far-reaching strategic and financial implications, especially for private hospitals in India. The adjustment of rates based on factors like accreditation, hospital type, and city tier is expected to impact hospital valuations, merger and acquisition activities, and investment prospects in the country’s healthcare industry.

Established in 1954, the CGHS offers medical coverage to central government employees, pensioners, and their families through a network of over 1,800 hospitals nationwide. While initially serving a targeted group, the scheme now represents a significant revenue source for many private healthcare facilities. Outdated reimbursement rates and delays in payments have deterred wider participation in CGHS. However, the recent rate revision aims to overcome these challenges and improve the financial viability of healthcare services associated with the scheme.

The 2025 policy revamp introduces a tiered pricing structure linked to quality standards. Reimbursements now depend on factors such as hospital accreditation, category, city classification, and ward entitlement. Hospitals accredited by the National Accreditation Board for Hospitals (NABH) receive the base rate, while non-NABH facilities receive 15% less. Hospitals located in Tier 2 cities receive 10% less than those in Tier 1, and Tier 3 city hospitals receive a 20% reduction compared to Tier 1 institutions. These changes aim to make top-tier hospitals more accessible to CGHS beneficiaries who have struggled to access premium healthcare services due to inadequate reimbursement rates.

The revised CGHS rates have immediate and structural implications for investors in the healthcare sector. Hospitals with strong accreditation and a significant CGHS patient base are likely to command higher prices, increased revenue predictability, and lower contracting risks with the government. On the other hand, hospitals without accreditation or located in smaller cities may face margin challenges, leading to consolidation among operators who are unable to leverage the CGHS effectively.

This shift in reimbursement rates is expected to influence valuation models across the healthcare industry, particularly in merger and acquisition deals. Hospitals that serve a large number of CGHS patients and hold NABH accreditation are poised to see improvements in key financial metrics like EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization). As investors and operators assess hospitals through the lens of accreditation, procedural diversity, and strategic city presence, the CGHS is no longer just a source of passive revenue but a critical factor shaping the healthcare landscape in India.